[Shanghai: By 2030, Shanghai’s drug supervision will achieve “strengthening the foundation and expanding capabilities, improving quality and efficiency, and making an overall leap forward”] On November 9, the Shanghai Food and Drug Safety Commission issued the “Shanghai’s 15th Five-Year Plan to Ensure Drug Safety and Promote High-Quality Development of the Pharmaceutical Industry.” It is mentioned that by 2030, Shanghai's drug supervision will achieve "strengthening the foundation, expanding capabilities, improving quality and efficiency, and making an overall leap forward." The chain of responsibilities has been further improved, and a responsibility system has been comprehensively established with the party and government sharing responsibilities, departmental linkage, enterprise main responsibilities, and social co-governance. Risk prevention and control has become more effective, the dynamic safety supervision mechanism for the whole process has been continuously consolidated, and systemic and regional safety risks have been effectively prevented. The reform efforts have been deepened, the review and approval system reform has been advanced in depth, and breakthroughs have been achieved in the pilot reform of key areas. The service supply is of higher quality, the working mechanism for biopharmaceutical development service innovation has been continuously improved, and registration guidance and service efficiency have been fully unleashed. Supervision guarantees have become more complete, supervision laws and regulations and scientific supervision systems have been comprehensively upgraded, talent team building has been continuously strengthened, and digital and intelligent supervision capabilities and supervision internationalization levels have been significantly improved. Better serve Shanghai in building an innovative highland for the biomedical industry with international influence and better meet the health needs of the people.